Monday, May 23, 2011

Suven granted seven product patents

 Suven Life Sciences announced the grant of seven product patents (two from Canada, three from India, one each from Eurasia and Japan) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases. These patents are valid through 2023, 2024 and 2025.

The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson’s syndrome and schizophrenia.

With these new patents, Suven has a total of five granted patents from Canada, 13 granted patents from India, nine granted patents from Eurasia and four granted from Japan for NCEs. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at phase-I or phase-II.

"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders which has an estimated $30 billion market potential globally,” said Venkat Jasti, Chief Exceutive Officer, Suven.

Source: ExpressPharma


Email address is not published
Remember Me

Write the characters in the image above